Acute Myeloid Leukemia Quallty of Life Questionnaire (AML-QOL) A validated and reliable quality of life instrument that is specific to patients with acute myeloid leukemia. Researchers at Fred Hutchinson Cancer center has developed a novel and validated quality of life instrument specifically designed for patients with acute myeloid leukemia (AML). Developed through an iterative process involving feedback from patients, medical providers, and psychometricians, the AML-QOL underwent rigorous testing and validation, including factor analysis and test-retest reliability studies with 202 patients. The final instrument includes 27 items organized into 5 domains, a Symptom Index, and a Summary Score. The AML-QOL has been shown to have high internal consistency, good test-retest reliability, and strong convergent and divergent validity when compared to a non-disease-specific instrument. Furthermore, the Summary Score demonstrates good sensitivity to change when anchored to patient perception of QOL change, providing a clinically meaningful difference of 8-10 points out of 100. The AML-QOL is a reliable and valid measure of quality of life for patients with AML and other aggressive myeloid neoplasms. <ul> <li>Assessing quality of life of patients with AML and other cancers</li> </ul> <ul> <li>Specifically designed for patients with acute myeloid leukemia (AML) and other aggressive myeloid neoplasms.</li> <li>Demonstrated high internal consistency, good test-retest reliability, and strong convergent and divergent validity.</li> </ul> <ul> <li>Stephanie Lee, M.D., MPH - David and Patricia Giuliani/Oliver Press Endowed Chair, Professor and Associate Director, Clinical Research Division</li> </ul> QoL fully developed and validated Copyright 18155LeeAMLQOL.pdf | QoL | AML | quality of life | patient reported outcome | AML-QoL-18-155